Richard E. Champlin
Non-Executive
Board of Commitee
Pfizer
United Kingdom
Biography
Dr. Champlin is in his twenty-fifth year at MD Anderson Cancer Center in Houston, Texas. He holds the titles of Chair, Department of Stem Cell Transplantation and Cellular Therapy; Professor of Medicine; and Associate Division Head, Division of Cancer Medicine. As an international leader in the field of hematopoietic stem cell transplantation (HSCT), Dr. Champlin pioneered the use of donor transplants and lower doses of chemotherapy, reducing mortality rates along the way. Under his leadership, the MD Anderson HSCT program grew to become the largest in the world. Dr. Champlin is board-certified in Internal Medicine, Medical Oncology and Hematology and received his MD (Alpha Omega Alpha) from the University of Chicago Pritzker School of Medicine prior to Residency and Fellowship at the University of California, LosAngeles. Additionally, Dr. Champlin has published approximately 700 original scientific and clinical research articles. He has Chaired or been a member of a multitude of professional organizations and committees, including Founding President of the American Society for Blood and Marrow Transplantation, Past Chair of the Center for International Blood and Marrow Transplantation Research, and is currently on the US Health Resources and Services Administration Advisory Council on Blood Stem Cell Transplantation. Awards include the John Mendelsohn Lifetime Scientific Achievement Award of MD Anderson Cancer Center, Division of Cancer Medicine and the Lifetime Achievement Award of the American Society for Blood and Marrow Transplantation.
Research Interest
Internal Medicine, Medical Oncology and Hematology